Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid biosynthesis pathway enzymes
- Molecular classification
- Enzyme, Transferase, Kinase, Synthase, Phosphatase
01
Overview
Sialic acid biosynthesis pathway enzymes are a group of intracellular enzymes that catalyze sequential reactions, beginning with conversion of UDP-GlcNAc to N-acetyl-D-mannosamine via the bifunctional UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE), then to N-acetylneuraminic acid (Neu5Ac) through synthase and phosphatase steps (NANS, NANP), which is then activated by cytidine monophosphate-sialic acid synthetase (CMAS). These activated forms are substrates for sialyltransferases, which transfer sialic acid onto cell-surface glycoproteins and glycolipids, modulating cellular communication, immune interactions, and pathogen recognition. Disruption or alteration of these pathway enzymes is implicated in cancer, inflammation, and certain congenital disorders, making them important metabolic and therapeutic targets but also raising challenges due to their ubiquitous roles in cell biology.
- Other names
- Sialic acid metabolic pathway enzymesSialic acid biosynthetic enzymesSialylation pathway enzymesSialic acid pathway proteins
02
Mechanism of action
Inhibition of enzyme activity (glycosyltransferase/sialyltransferase inhibitors block sialylation on glycoproteins); Modulation of pathway flux (altering sialic acid levels impacts cellular signaling and immune recognition)
03
Biological functions
Synthesis and activation of sialic acidModification and transfer of sialic acid to glycoconjugatesCellular communicationModulation of immune responseGeneration of cell-surface antigens
04
Disease associations
Cancer (disrupted sialylation is associated with tumor invasion and immune evasion)InflammationInfection (pathogen mimicry utilizes sialylation)Congenital metabolic disorders (e.g., sialuria)
05
Safety considerations
Altered sialylation can impact immune tolerance and pathogen resistanceBroad targeting of pathway may disrupt essential cell functions and developmental processesOff-target effects due to conserved pathway in multiple tissues
06
Interacting drugs
No clinically approved drugs directly target the full pathway; experimental molecules targeting GNE or sialyltransferases have been reported in preclinical research
07
Biomarkers
Sialic acid levels on cell surfacesSialylated glycan patternsModified sialic acid structures (e.g., Neu5Gc, O-acetylation)Sialyltransferase expression
Beyond the preview
Go deeper on Sialic acid biosynthesis pathway enzymes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sialic acid biosynthesis pathway enzymes.